In a filing, ANI Pharmaceuticals Inc revealed its SR. VP, GENERAL COUNSEL & SEC. Cook Meredith unloaded Company’s shares for reported $25952.0 on Jul 14 ’25. In the deal valued at $64.88 per share,400 shares were sold. As a result of this transaction, Cook Meredith now holds 78,945 shares worth roughly $5.2 million.
Then, Cook Meredith sold 400 shares, generating $24,548 in total proceeds. Upon selling the shares at $61.37, the SR. VP, GENERAL COUNSEL & SEC. now owns 79,345 shares.
Before that, Gutwerg Ori sold 881 shares. ANI Pharmaceuticals Inc shares valued at $52,922 were divested by the SVP, GENERICS at a price of $60.07 per share. As a result of the transaction, Gutwerg Ori now holds 89,897 shares, worth roughly $5.92 million.
H.C. Wainwright initiated its ANI Pharmaceuticals Inc [ANIP] rating to a Buy in a research note published on July 10, 2025; the price target was $84. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. JP Morgan began covering ANIP with “an Overweight” recommendation on March 12, 2025. Leerink Partners started covering the stock on December 11, 2024. It rated ANIP as “an Outperform”.
Price Performance Review of ANIP
On Tuesday, ANI Pharmaceuticals Inc [NASDAQ:ANIP] saw its stock jump 0.67% to $65.87. Over the last five days, the stock has gained 2.60%. ANI Pharmaceuticals Inc shares have risen nearly 3.16% since the year began. Nevertheless, the stocks have risen 19.16% over the past one year.
How much short interest is there in ANI Pharmaceuticals Inc?
A steep rise in short interest was recorded in ANI Pharmaceuticals Inc stocks on 2025-07-15, growing by 0.11 million shares to a total of 2.13 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 2.01 million shares. There was a rise of 5.31%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 11, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $68 price target.
